Become a Readings Member to make your shopping experience even easier. Sign in or sign up for free!

Become a Readings Member. Sign in or sign up for free!

Hello Readings Member! Go to the member centre to view your orders, change your details, or view your lists, or sign out.

Hello Readings Member! Go to the member centre or sign out.

 
Paperback

Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy: Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans

$241.99
Sign in or become a Readings Member to add this title to your wishlist.

This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy.

The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen. Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed. It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.

The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.

Read More
In Shop
Out of stock
Shipping & Delivery

$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout

MORE INFO
Format
Paperback
Publisher
International Agency for Research on Cancer
Country
France
Date
21 March 2008
Pages
678
ISBN
9789283212911

This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy.

The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen. Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed. It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.

The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.

Read More
Format
Paperback
Publisher
International Agency for Research on Cancer
Country
France
Date
21 March 2008
Pages
678
ISBN
9789283212911